A recent study in a mouse model of colitis has demonstrated that interleukin (IL)-13, through inhibition of the mixed type 1 and type 17 T-helper cell inflammatory response, has a protective effect. the decoy receptor Il-13R alpha 2 inhibits this protective effect, suggesting blockade of IL-13R alpha 2 as a potential therapy for patients with IBD.
IBD Of mice and men-shedding new light on IL-13 activity in IBD
Danese S
2011-01-01
Abstract
A recent study in a mouse model of colitis has demonstrated that interleukin (IL)-13, through inhibition of the mixed type 1 and type 17 T-helper cell inflammatory response, has a protective effect. the decoy receptor Il-13R alpha 2 inhibits this protective effect, suggesting blockade of IL-13R alpha 2 as a potential therapy for patients with IBD.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
